DRUG	SUPPLIED	DOSE	COMMENTS
DEFIBROTIDE (Paeds) (Defitelio) Mechanism of action: Defibrotide protects the endothelium lining blood vessels from damage by fludarabine, a chemotherapy drug, and from other insults like serum starvation. It also appears to increase t-PA function and decrease plasminogen activator inhibitor-1 activity. Ref: 44, 465, 467 Last update: 2021-11-12	Injection: 80 mg/mL (2.5 mL)	Treatment of sinusoidal obstruction syndrome (SOS) aka veno-occlusive disease (VOD) Children and adults 6.25 mg/kg/dose IV Q6H (use baseline weight prior to preparative conditioning regimen)	Possible adverse effects: hypotension, bleeding, nausea, vomiting. Do not give concomitantly with anti-coagulants (with the exception of heparin-locks). Do not use in patients with active and/or clinically significant bleeding. Discontinue 2 hours prior to invasive procedures; may resume when risk of bleeding is resolved. There is no known reversal agent for defibrotide. Standard Prescription: Defibrotide __ mg IV Q6H (__ mg/kg/dose)